patent.fyi
Applications  /  US 2026/0355168
United States Patent Application Publication

US 2026/0355168 A1

Published
Nov 12, 2026
Filed
Aug 29, 2023
Earliest date on the face
Aug 29, 2022
Classification
A61K 31/4439
First published here
Nov 19, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.2Fixed fused ring junction

What ifWhat if a permanent carbon–carbon bond closed the ring junction in every compound?
Claim language“an optional bond”

A fused bicyclic scaffold shares a carbon–carbon bond between its two rings. The shared bond limits rotation at the junction and fixes the relative orientation of substituents on the two rings.

1.5Thioether sulfur at X5

What ifWhat if X5 were a divalent sulfur atom in a saturated ring?
Claim language“N or O”

A thioether sulfur joins the two neighboring ring carbons. The sulfur provides a polarizable contact surface, and its carbon–sulfur bonds increase the spacing between the neighboring carbons relative to an ether linkage.

1.6Difluoromethylene linker at X6

What ifWhat if a difluoromethylene group occupied X6?
Claim language“CH2 or N(R7)”

The difluoromethylene carbon connects the same two neighboring atoms through single bonds. Its two carbon–fluorine bonds change the local electrostatic surface while retaining a single tetrahedral atom at the linkage.

1.7Nitrile group at R1

What ifWhat if a nitrile group occupied R1?
Claim language“═O, halogen, hydroxyl, alkyl, haloalkyl, or alkoxy”

The nitrile attaches through its carbon and projects a linear carbon–nitrogen triple bond from the scaffold. The terminal nitrogen accepts a hydrogen bond when the pocket places a donor along the nitrile axis.

1.8Methylsulfonyl group at R6

What ifWhat if R6 were a methylsulfonyl group bonded to A through sulfur?
Claim language“—N(R8)2, halogen, hydroxyl, alkyl, haloalkyl, alkoxy, —S(O)tN(H)-alkylene-aryl”

The substituent attaches through sulfur in an A–S(═O)₂–CH₃ linkage. The two sulfonyl oxygens provide hydrogen-bond acceptor sites, and the terminal methyl group occupies a small nonpolar volume.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Other field of use

Candidate screening in veterinary oncology

A veterinary oncology laboratory places tumor cells from canine mammary biopsies in low-attachment culture wells. The laboratory adds the compound to test wells and vehicle alone to matched control wells. The assay measures spheroid number, spheroid diameter, and viable cell count to distinguish changes in aggregation from changes in cell number.

Component substitution

Adhesion measurement by electrical impedance

Gold microelectrodes replace the linked detectable moiety as the source of the assay signal. Tumor cells settle onto extracellular matrix-coated electrodes in wells that receive the compound or vehicle. The reader records impedance before and after exposure, and matched wells provide cell viability measurements to help interpret changes in electrode coverage.

Parameter or scale variation

Concentration series for spheroid growth

A 96-well low-attachment plate holds 2,000 tumor cells per well in 100 microliters of medium. Triplicate wells receive the compound at 0.03, 0.1, 0.3, 1, 3, or 10 micromolar with the same final vehicle concentration, and matched wells receive vehicle alone. A bright-field microscope records images at 0, 24, and 72 hours for measurement of spheroid count and projected area.

Combination with existing systems

Perfused chip for tumor invasion

A two-channel microfluidic chip places a collagen gel between a tumor cell channel and a perfusion channel. The perfusion channel carries medium containing the compound, and a matched chip receives medium with vehicle alone. Time-lapse microscopy tracks cells crossing the tumor–gel interface and measures their penetration depth over time.

Compound exposure measured by microdialysis

A tumor microdialysis probe connects to a low-flow pump and a timed fraction collector in an in vivo study. After compound administration, the probe collects serial samples of tumor extracellular fluid, and liquid chromatography coupled to tandem mass spectrometry quantifies the compound in each fraction. Probe recovery calibration converts the measured concentrations into estimates of extracellular exposure, which are aligned with the times of tumor imaging.

Automated or data-driven variant

Automated tracking of cell dispersal

A motorized microscope acquires time-lapse phase-contrast images of compound-treated and vehicle-treated spheroids embedded in a transparent matrix. Software segments the initial spheroid boundary, detects cells that leave it, and links detections between frames by spatial proximity. The software reports the number of departing cells, their speeds, and their radial displacements from the initial boundary.

Specific version of a part

Pyridine nitrogen at X1

X1 is N(H)₀ at a pyridine-like position in a six-membered aromatic ring. In the neutral form, its lone pair lies in the ring plane and accepts a hydrogen bond.

Paired methyl groups at R8

Both R8 groups are methyl in an —N(R8)₂ substituent, giving an —N(CH₃)₂ group. The nitrogen has two methyl bonds and one bond to the scaffold, and it accepts a proton under acidic conditions.

Methylene carbon at X2

X2 is C(H)₂, with m set to 2. The carbon forms two single bonds to its neighbors and carries two hydrogens in a saturated ring segment.

Two sulfur bonded oxygens

The value of t is 2 in an R6 group of the form —S(═O)₂–NH–CH₂–phenyl. The sulfonyl oxygens act as hydrogen-bond acceptors, and the nitrogen carries one hydrogen and connects to the phenyl ring through a methylene group.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 2009/0252680 A1
Published
Oct 8, 2009
Filed
Oct 30, 2007
Class
A61K 51/04
Document BUS 9,604,922 B2
Published
Mar 28, 2017
Filed
Feb 24, 2015
Class
C07C 311/06
Claim 1
Document A
Document B
1.1administering to the subject a compound of formula (I): or a pharmaceutically acceptable salt, tautomer, or solvate thereof
A method of treating a neurological disease selected from multiple sclerosis and psoriasis by administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof: wherein: R1 is C1-C6 alkyl;
B · US 9,604,922 B2 · claim 8
1.2wherein, a dashed line is an optional bond
1.3A is cycloalkyl, aryl, heteroaryl, or heterocyclyl, each of which is optionally substituted with one or more R6
La is C1-C6 alkyl, C3-C10 carbocycle, C6-C10 aryl, heterocycle comprising one or two 5- or 6-member rings and 1-4 heteroatoms selected from N, O and S, or heteroaryl comprising one or two 5- or 6-member rings and 1-4 heteroatoms selected from N, O and S, wherein the alkyl, carbocycle, aryl, heterocycle, or heteroaryl groups are optionally, independently substituted one or more times with halogen;
B · US 9,604,922 B2 · claim 8
1.4X1, X2, and X3 are each independently C(H)m or N(H)n
In the formula (1), A1, A2, A3 and A4 independently represent a carbon or nitrogen, and it is necessary that at least one of these represents a carbon.
A · US 2009/0252680 A1 · ¶ 23
1.5X4 and X5 are each independently N or O
1.6X6 is CH2 or N(R7)
1.7R1 and R2 are each independently absent, ═O, halogen, hydroxyl, alkyl, haloalkyl, or alkoxy
A compound represented by the following formula (1), or a salt thereof: wherein each of A1, A2, A3 and A4 independently represents a carbon or nitrogen, R1 is a group selected from the group consisting of hydrogen, hydroxyl group, carboxyl group, sulfuric acid group, amino group, nitro group, cyano group, non-radioactive halogen substituents, alkyl substituents with 1-4 carbon atoms, and alkoxy substituents with 1-4 carbon atoms, and R2 is a radioactive halogen substituent, p
A · US 2009/0252680 A1 · claim 1
R2 is C1-C10 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, OH, C6-C10 aryl, C3-C10 carbocycle, heterocycle comprising one or two 5- or 6-member rings and 1-4 heteroatoms selected from N, O and S, or heteroaryl comprising one or two 5- or 6-member rings and 1-4 heteroatoms selected from N, O and S, wherein the alkyl, alkenyl, alkynyl, aryl, carbocycle, heterocycle, or heteroaryl groups are optionally, independently substituted one or more times with C1-C6 alkyl, OH, O(C1-C6 alkyl), oxo
B · US 9,604,922 B2 · claim 8
1.8each R6 is independently —N(R8)2, halogen, hydroxyl, alkyl, haloalkyl, alkoxy, —S(O)tN(H)-alkylene-aryl or alternatively R6 and R7 together with the atom(s) to which they are attached can form a 4- to 7-membered heteroaryl or heterocyclyl
R2 is C1-C10 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, OH, C6-C10 aryl, C3-C10 carbocycle, heterocycle comprising one or two 5- or 6-member rings and 1-4 heteroatoms selected from N, O and S, or heteroaryl comprising one or two 5- or 6-member rings and 1-4 heteroatoms selected from N, O and S, wherein the alkyl, alkenyl, alkynyl, aryl, carbocycle, heterocycle, or heteroaryl groups are optionally, independently substituted one or more times with C1-C6 alkyl, OH, O(C1-C6 alkyl), oxo
B · US 9,604,922 B2 · claim 8
1.9R7 and R8 are each independently H, halogen, hydroxyl, alkyl, alkoxy, or haloalkyl
R3 is H, C1-C10 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, SO2R4, or S(O)R4, wherein the alkyl, alkenyl, or alkynyl groups are optionally, independently substituted one or more times with C1-C6 alkyl, OH, O(C1-C6 alkyl), oxo, halogen, NH2, N(H)(C1-C6 alkyl), N(C1-C6 alkyl)2, SO2H, SO2(C1-C6 alkyl), CHO, CO2H, CO2(C1-C6 alkyl), or CN;
B · US 9,604,922 B2 · claim 8
1.10m is 0, 1, or 2
1.11n is 0 or 1
1.12t is 0, 1, or 2.

An empty cell means only that no passage was reproduced there.

Statements in these documents
More specifically, the invention relates to a compound useful for amyloid detection at lesion sites in diagnosis of Alzheimer's disease and other diseases with amyloid accumulation.
A · US 2009/0252680 A1 · ¶ 1
At present, it is practically impossible to establish a definite diagnosis of AD while an AD patient is still alive, because the definite diagnosis requires a biopsy of a lesion (Non-Patent Document 1).
A · US 2009/0252680 A1 · ¶ 5
For example, dimethyl fumarate is known to cause side effects upon oral administration, such as flushing and gastrointestinal events including nausea, diarrhea, and/or upper abdominal pain in subjects.
B · US 9,604,922 B2 · ¶ 7
Further, in the use of a drug for long-term therapy, it is desirable that the drug be formulated so that it is suitable for once- or twice-daily administration to aid patient compliance.
B · US 9,604,922 B2 · ¶ 7
Cite aspatent.fyi, US 2026/0355168 A1, claim 1, first published 2026-11-19T09:07:06-05:00, https://patent.fyi/US20260355168/, SHA-256 e5ded41b090e159326c773fd7f445ac262a36c9f8cfb0b087f314af91425f61b
First published
Permanent addresshttps://patent.fyi/US20260355168/
Content fingerprint (SHA-256)e5ded41b090e159326c773fd7f445ac262a36c9f8cfb0b087f314af91425f61b
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi